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ARTICLE

First-Pass CYP3A-Mediated Metabolism of Midazolam in
the Gut Wall and Liver in Preterm Neonates
Janneke M. Brussee 1, Huixin Yu1, Elke H. J. Krekels 1, Berend de Roos1, Margreke J. E. Brill2,
Johannes N. van den Anker3,4,5, Amin Rostami-Hodjegan6,7, Saskia N. de Wildt3,8 and Catherijne A. J. Knibbe1,9*

To predict first-pass and systemic cytochrome P450 (CYP) 3A-mediated metabolism of midazolam in preterm neonates, a
physiological population pharmacokinetic model was developed describing intestinal and hepatic midazolam clearance in
preterm infants. On the basis of midazolam and 1-OH-midazolam concentrations from 37 preterm neonates (gestational age
26–34 weeks) receiving midazolam orally and/or via a 30-minute intravenous infusion, intrinsic clearance in the gut wall and
liver were found to be very low, with lower values in the gut wall (0.0196 and 6.7 L/h, respectively). This results in a highly
variable and high total oral bioavailability of 92.1% (range, 67–95%) in preterm neonates, whereas this is around 30% in adults.
This approach in which intestinal and hepatic clearance were separately estimated shows that the high bioavailability in
preterm neonates is explained by, likely age-related, low CYP3A activity in the liver and even lower CYP3A activity in the gut
wall.
CPT Pharmacometrics Syst. Pharmacol. (2018) 7, 374–383; doi:10.1002/psp4.12295; published online 10 May 2018.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
þ That the CYP enzymes are present in the gut wall
and liver, but a different contribution of the gut and the
liver to the first-pass effect may be anticipated in children as compared with adults, due to different rates of
maturation of intestinal and hepatic enzymes in infants
and children.
WHAT QUESTION DID THIS STUDY ADDRESS?
þ That first-pass metabolism in the gut wall and liver
can be predicted for the CYP3A substrate midazolam
using a state-of-the-art physiological population PK
modeling approach.

The neonatal body is undergoing many dynamic changes
in the first months of life,1 with preterm neonates showing
delayed maturation of many organs as compared with term
neonates. This results among others in an altered and
highly variable capacity to deal with xenobiotics, including
drugs.2,3 Metabolic capacity is an important determinant
for the bioavailability and systemic clearance of drugs that
are subject to metabolic clearance. Bioavailability impacted
by intestinal and hepatic metabolism and systemic clearance impacted by hepatic metabolism are the two main
drivers of drug exposure. Interindividual differences in
these two parameters are, therefore, two of the main
1

WHAT DOES THIS STUDY ADD TO OUR
KNOWLEDGE?
þ A very low first-pass effect by intestinal and hepatic
CYP3A-mediated metabolism was found for midazolam
in preterm neonates, yielding much higher bioavailability of midazolam in preterm neonates compared with
adults. Furthermore, intestinal CYP3A activity, represented by intrinsic clearance in the gut wall, was much
lower than hepatic CYP3A activity, represented by the
intrinsic clearance in the liver.
HOW MIGHT THIS CHANGE DRUG DISCOVERY,
DEVELOPMENT, AND/OR THERAPEUTICS?
þ Characterization of gut wall and hepatic CYP3A
activity enables quantitative predictions of first-pass
and systemic metabolism of midazolam and potentially
other CYP3A substrates in preterm neonates.

drivers of differences in drug dose requirements between
patients.
Physiological parameters that affect drug metabolism
include protein binding, blood flow, and intrinsic clearance,
the latter of which represents metabolic capacity.3,4 Developmental changes in albumin concentrations5 and drug protein binding6 have been reported in neonates, as well as
changes in cardiac output,5 which influence the intestinal
and hepatic blood flow.7 However, there is limited knowledge on the development of intrinsic clearance of many
drugs, especially with respect to the intestinal and hepatic
enzyme activity in preterm infants.
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Cytochrome P450 (CYP) is an enzyme family involved in
drug metabolism and its ontogeny in children has been studied both in vitro and in vivo.8 The CYP3A subfamily (i.e.,
CYP3A4, CYP3A5, and CYP3A7) is involved in metabolism
of many clinical important drugs with midazolam commonly
used as a probe drug to reflect combined CYP3A activity.9,10
Midazolam is a benzodiazepine, often used for sedation in the
neonatal intensive care unit,11 and its CYP3A-mediated clearance have been reported to be lower in neonates, infants,
and children, compared with adults.12 As CYP3A resides in
both the gut wall and the liver,13 it is of interest to distinguish
between intestinal and hepatic CYP3A activity with respect to
their roles in first-pass metabolism, particularly because intestinal and hepatic enzymes may mature at different rates.
Besides CYP3A activity in the gut wall and liver, important
factors that may affect the absorption and metabolism of
drugs in the gut wall are among others the intestinal surface
area and the permeability of the endothelium.14 Preterm
infants have a smaller surface area and are known to have
an underdeveloped intestinal barrier,15 resulting in a higher
intestinal permeability in neonates with gestational ages of
<34 weeks.16
To describe and predict pharmacokinetic (PK) profiles and
drug exposure in patients, different types of models have
been used based on availability of data and their purpose.
These models range from relatively simple, empirical models,
to more complex (semi-)physiologically based PK models.17
Empirical models often lack predictive value outside the studied population, whereas large physiologically based pharmacokinetic models are not always identifiable and may depend
on system parameters that are difficult to determine experimentally in children. Therefore, a hybrid of these models is
useful not only to determine PK of a single drug but also to
obtain insight into drug independent systems information
when the models are used for several drugs simultaneously.18
In this analysis, we used a physiological population PK modeling approach, in which we account for the attributes of the
gastrointestinal tract and use available systems data together
with PK information from the preterm population to describe
intestinal and hepatic midazolam clearance and ultimately predict first-pass and systemic metabolism by CYP3A of midazolam in preterm neonates.
METHODS
Data
Thirty-seven preterm neonates (gestational ages ranging from
26–34 weeks, birth weights 745–2,135 grams) of a previously
published dataset from the neonatal intensive care unit of the
Sophia’s Children Hospital in Rotterdam were included.19,20 At
the time of the clinical investigation, their postnatal ages
ranged from 3–11 days and their body weights between 770
and 2,030 grams. These infants were randomly assigned to
receive 0.1 mg/kg midazolam orally via a nasogastric tube
(n 5 13) or intravenously via a 30-minute infusion (n 5 25). If,
after 72 hours, the participating infants still met the inclusion
criteria, they received another dose of midazolam but this
time via the other route. Midazolam and its primary metabolite
1-OH-midazolam were measured in plasma 0.5, 1, 2, 4, 6,
12, and 24 hours postdose19,20 and measurements below the

lower limit of quantification were discarded (<1% and <2% of
329 and 153 midazolam and 1-OH-midazolam measurements, respectively).
Model development
Structural physiological pharmacokinetic model. Physiological population PK modeling was performed using first-order
conditional estimation with interaction in NONMEM version
7.3 (ICON, Globomax, Ellicott, MD) with Pirana 2.9.0 and R
(version 3.3.1) and R-studio (version 0.98.1078) for processing of the runs and visualization of data.
A physiological population PK model, earlier described by
Yang et al.,21 Frechen et al.,22 and Brill et al.,23 was applied
to describe the data (Figure 1). For this, using the blood:
plasma ratio and the measured molar concentrations in
plasma, the drug and metabolite molar concentrations in
blood were calculated to be able to be used in the wellstirred model. The model describes physiological compartments representing the gut wall, the portal vein, and the
liver, and an empirical central compartment for midazolam
and 1-OH-midazolam, representing the blood circulation
and equilibrating tissue.21,22 For midazolam and 1-OHmidazolam, also the addition of empirical peripheral compartments was evaluated. The fraction of midazolam metabolized into 1-OH-midazolam was assumed to be 1.
Tissue volumes for the physiological compartments in the
preterm neonatal population were allometrically scaled from
tissue volumes of a term neonate7 with a fixed exponent
of 1 (Table 1 5–7,24–31,48). Volume of the portal vein was
assumed to be 77.8% of the hepatic volume.24 The hepatic
blood flow was assumed to allometrically scale from a term
neonate7 with a fixed exponent of 0.75. Blood flows in the
other tissues were assumed to be proportional to the
hepatic blood flow (Table 15,7,25,32).
The well-stirred model was used to quantify the hepatic
extraction of midazolam (EH) and 1-OH-midazolam (EH,M):
EH 5

CLint;H 3fu;B

Qh 1 CLint;H 3fu;B

(1)

where CLint,H is the estimated intrinsic clearance in the liver
based on unbound blood concentrations, fu,B is the fraction
unbound drug concentration in blood, and Qh is the hepatic
blood flow.
For gut wall metabolism into 1-OH-midazolam (EG), the
Qgut model was applied25:
EG 5

CLint;G 3fu;G

Qgut 1 CLint;G 3fu;G

(2)

where CLint,G is the estimated intrinsic clearance in the gut
wall based on unbound concentrations, fu,G is the fraction
unbound drug concentration in the gut wall, and Qgut is the
local blood flow, which is defined by25:
Qgut 5

Qvilli 3CLperm
Qvilli 1CLperm

(3)

where Qvilli is the villous blood flow and CLperm is the permeability of the drug through the enterocytes in the gut
www.psp-journal.com

Midazolam Metabolism in the Gut Wall and Liver in Preterm Neonates
Brussee et al.
376

Figure 1 Schematic representation of the model for midazolam and the 1-OH-midazolam metabolite. CLint, the intrinsic clearance in
the blood; E, extraction ratio; F, bioavailability in the gut wall (gut, G) and the liver (hepatic, H); Ka indicates the absorption rate constant and the fraction unbound in blood and gut wall are described with fu,B and fu,G, respectively. Blood flows are represented by Q; in
the micro villi (Qvilli), portal vein (QPV), hepatic artery (QHA), and the hepatic blood flow (Qh). Parameters relating to the metabolite are
indicated with subscript M. Intrinsic gut wall (CLG,int) and intrinsic hepatic clearance (CLH,int and CLH,int,M), as well as volume of distribution (for midazolam and 1-OH-midazolam), values were estimated in the model. Total plasma clearance of midazolam was derived
using Eq. 8, and the bioavailability in the gut wall (Fg), liver (Fh), and the total oral bioavailability (Ftotal) were derived based on Eqs. 1,
2, and 5.

wall, which depends on the effective intestinal permeability
per unit surface area25 and the intestinal surface area. The
intestinal surface area (A) was calculated based on the net
cylindrical surface area of the small intestine using Eq. 4.
A5 2p3r3h

(4)

in which r is the intestinal radius of 1 cm,26 and h the intestinal length of 2.736 3 (WT[g])0.512 cm.27 The fraction
unbound in the gut (fu,G) for both midazolam and 1-OHmidazolam was assumed 1.25 The absorption rate constant
could not be estimated and was assumed to be 10 h21,
which entails an expected maximum concentration around
12.5 minutes (time of maximum plasma concentration
(Tmax)). A sensitivity analysis was performed with values for
ka ranging from 4.16–25 h21, resulting in a Tmax between 5
and 30 minutes postdose. The oral bioavailability was calculated with Eq. 5:
Ftotal 5 Fa 3 Fg 3 Fh

(5)

where Fa is the fraction absorbed, which is assumed 1 for
midazolam,10 Fg is the gut wall bioavailability, equal to 1
minus Eg, and Fh is the hepatic bioavailability, and Fh 5 1 –
Eh.
The fraction unbound in blood for both midazolam and 1OH-midazolam in blood was calculated based on the formula of McNamara and Alcorn6:
CPT: Pharmacometrics & Systems Pharmacology

fu;B;pediatric 5
11

1
ð12fu;B;adult Þ 3½P pediatric

(6)

½P adult 3fu;B;adult

where fu,pediatric and fu,adult are the fraction unbound of the
drug in blood for preterm neonates and adults, respectively,
and [P]pediatric and [P]adult are the plasma albumin concentrations in preterm neonates and adults, respectively. These
albumin concentrations are calculated based on an agebased formula from Johnson et al.5 (Table 1) and the fractions unbound of midazolam and 1-OH-midazolam in adults
were reported in literature.28,29 The fraction unbound in
blood and hematocrit were used to calculate the blood:
plasma ratios for midazolam and 1-OH-midazolam using
the formula of Maharaj et al.30:
B : P ratio 5 11 ½Hem 3 ðfu; B 3 Kp21Þ

(7)

where B:P ratio is the blood:plasma ratio, Hem is the
hematocrit in preterm neonates (45%),31 fu,B is the fraction
unbound in the blood, and Kp is the unbound partition coefficient of red blood cells (assumed to be constant between
adults and children).30
Total plasma clearance by the liver was calculated based
on33:
CLplasma 5

Qh 3fu 3CLh;int

Qh1 fu 3CLh;int =ðB : P ratio Þ

(8)
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Table 1 Parameter values for physiological and drug specific parameters in the model
Parameter definition
(unit)

Formula for
calculation

Parameter

Value

References

Tissue volumes (L)
Liver

Vh

Portal vein

Vpv

Vpv 5 0.778 3 Vh

(24)

Gut

Vgw

Vgw,3.55kg neonate 3
(WT/3.55)

(7)

Vh,3.55kg neonate 3
(WT/3.55)
Vh,3.55kg

(7)

neonate 5 0.120

neonate 5 0.050

Vgw,3.55kg
Tissue blood flows (L/h)
Hepatic blood flow

Qh

Portal vein

Qpv

0.75 3 Qh

(5, 32)

Hepatic artery

Qha

0.25 3 Qh

(5, 32)

Small intestine

Qin

0.4 3 Qh

(25)

Mucosa

Qmuc

0.8 3 Qin

(25)

Microvilli

Qvilli

0.6 3 Qmuc

(25)

Qh,3.55kg neonate 3
(WT/3.55)0.75
Qh,3.55kg

(7)

neonate 5 13.2

Plasma proteins
Plasma albumin
concentration (g/L)

[P]pediatric

Hematocrit (%)

Hem

1.1287 3
ln(Age[yr]) 1 33.746

27.1

(5)

–

0.45

(31)

2p 3 r 3 h

5.97

r: (26)

37.0

[P]adult
Intestinal surface area and
permeability
Intestinal surface area
(dm2)

A

With radius r 5 1 cm and
length
h 5 2.7363(WT[g])0.512 cm
Permeability through the
enterocyte (L/h)

CLperm

CLperm 5 Peff,man [dm/h] 3
A [dm2]

h: (27)

0.95

(25)

(10)

Midazolam
Fraction absorbed

Fa

–

1

Absorption rate constant

Ka (h21)

–

10

–

Blood:plasma ratio

B:P ratio

11 [Hem 3 (fu,B 3 Kp21)]
Kp 5 1

0.568

(30)

1

(25)

Fraction unbound in gut

Fu,G

–

Fraction unbound in blood

Fu,B

1
11

Fu,adult

ð12fu;adult Þ 3½P pediatric
½P adult 3fu;adult

0.04094

(6)

0.0303

(28)

Peff,man

–

4.4 3 1024

(25)

Fraction midazolam
metabolized into 1-OHmidazolam

fM

–

1

–

Blood:plasma ratio

B:P ratio

11 [Hem 3 (fu,M 3 Kp21)]
Kp 5 1

0.613

(30)

Fraction unbound in blood

Fu,M

1

0.1394

(6)

0.106

(29)

Effective intestinal
permeability per unit
surface area (cm/s)
1-OH-midazolam

11

fu,M,adult

in which Qh is the hepatic blood flow, fu the fraction
unbound in plasma, and CLh,int the intrinsic hepatic
clearance.

ð12fu;M;adult Þ 3½P pediatric
½P adult 3fu;M;adult

To evaluate the structural identifiability or our nonlinear
model, we used the Differential Algebra for Identifiability of
Systems software.34
www.psp-journal.com
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Statistical model
Interindividual variability was included in the model as a
log-normal distribution:
hi 5hTV 3e gi

(9)

where hi is individual parameter estimate for individual i,
hTV is the typical value of the parameter in the studied population, and gi is a random variable from a normal distribution with a mean of zero and estimated variance of x2.
Residual unexplained variability was modeled using a
combined error model. The jth observed concentration (Y)
of the ith individual was modeled according to:
Yij 5 Cpred; ij 3 ð11E1ijÞ 1 E2ij

(10)

where Cpred,ij is the jth predicted midazolam concentration
of the ith individual, E1ij and E2ij are random variables from
normal distributions with a mean of zero and estimated variance of r2, representing the proportional and additive component of the error model, respectively.
Covariate analysis
A covariate analysis on the clearance and volume parameters was performed in which the following covariates were
tested for statistical significance: body weight at birth, gestational age, gender, and mechanical respiratory support,
and furthermore body weight, postmenstrual age, and postnatal age per occasion (e.g., at the day of dose administration). There was no missing covariate information for any
subject.
For categorical covariates, separate typical values (hTV)
for the two populations were estimated. Continuous covariates were tested using a linear (Eq. 11) or power (Eq. 12)
function.
hi 5hTV 3ð11hcov 3ðCOV 2COVmed Þ

hCOV
COV
hi 5hTV 3
COVmed

Sensitivity analysis
To evaluate the assumptions made in the model, a sensitivity analysis was performed using simulations in Berkeley
Madonna software (Berkeley Madonna, version 8.3.18).35
Parameter values for tissue volumes and blood flows as
well as intestinal length and the fraction unbound in blood
were increased and decreased by 50% and the impact on
predicted midazolam concentrations was evaluated. Furthermore, the impact of the assumptions on the estimated
PK parameters was assessed by re-estimating the model
with the increased/decreased values for tissue volumes and
blood flows as well as intestinal length and the fraction
unbound in blood.
Dose simulations
To illustrate the impact of first-pass metabolism on midazolam and 1-OH-midazolam exposure in preterm neonates,
model-based simulations of concentration-time profiles
were performed with our model. A dose of 0.1 mg/kg midazolam was simulated as oral administration or as a 30minute intravenous infusion in 37 preterm neonates with
the same patient characteristics as the individuals in our
dataset.

(11)
(12)

where hi is the individual parameter estimate for the individual i, hTV is the typical value of the parameter in the studied
population with a median value (COVmed) of the covariate
(COV), and hCOV the estimated slope or exponent for a linear or power function, respectively.
Model evaluation
Discrimination between different structural models was
made by comparison of the objective function value (OFV;
i.e., 22 3 log-likelihood). A decrease of 3.84 points in the
OFV between nested models was considered statistically
significant (P < 0.05). Furthermore, goodness-of-fit plots
(individual-predicted and population-predicted vs. observed
concentrations and conditional weighted residuals vs. time
and population predicted concentrations) of midazolam and
1-OH-midazolam were assessed. In addition, the confidence interval of the parameter estimates and visual
improvement of the individual plots were used to evaluate
the models.
CPT: Pharmacometrics & Systems Pharmacology

For inclusion of covariates, a decrease in OFV of 6.64
points (P < 0.01) was considered statistically significant,
whereas for the backward deletion a more stringent P
value (P < 0.005; DOFV >7.88) was used. Furthermore, to
retain a covariate in the model, the interindividual variability
in the PK parameter should decrease and in a plot of the
covariate vs. the interindividual variability in the PK parameter, the data points should be randomly scattered around
zero.
The model was further internally evaluated using two
different methods, a bootstrap analysis (n 5 200) and a normalized prediction distribution error analysis (see Supplementary Figures S1 and S2).

RESULTS
Using the physiological population PK model, as depicted
in Figure 1, which was structurally identifiable according to
the Differential Algebra for Identifiability of Systems analysis,34 the PK data in preterm neonates were well described.
Based on the available data, intrinsic CYP3A clearance in
the gut wall and liver were estimated to be 0.0196 (relative
standard error (RSE) 178%) and 6.7 (RSE 10%) L/h,
respectively (Table 2). Distribution volumes for midazolam
and its metabolite in blood were estimated to be 3 (RSE
11%) and 2.7 (RSE 43%) L, respectively, and the addition
of peripheral compartments for either midazolam or 1-OHmidazolam did not improve the model. No additional covariates could be identified for intrinsic clearance and volume
of distribution. The model was graphically and numerically
evaluated (Table 2, and Supplementary Figures S1 and
S2) and generally the model parameters described the PK
data of both the midazolam and 1-OH-midazolam well. The
additive errors were fixed to very small numbers (Table 2).
Goodness-of-fit plots (Supplementary Figure S1) showed
that the model adequately describes the data, albeit with a
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Table 2 Parameter estimates and bootstrap results of the physiological population PK model
Parameter definition

Parameter

Value (RSE%)
[shrinkage %]

Bootstrap mediana

Bootstrap 90% CI

Midazolam
Intrinsic hepatic clearance

CLH,int (L/h)

Intrinsic gut wall clearance

CLG,int (mL/h)

Volume of distribution

6.7 (10)

6.6

5.0–8.7

19.6 (178)

14.0

0.2b2319

V (L)

3.0 (11)

3.0

2.4–3.7

Intrinsic hepatic clearance

CLH,int,M (L/h)

8.9 (22)

7.7

3.5–11.2

Volume of distribution

VM (L)

2.7 (43)

2.9

1.5–7.2

Intrinsic hepatic clearance

x2 CLH,int

0.887 (26) [3]

0.851

Intrinsic gut wall clearance

x2 CLG,int

–

–

–

Volume of distribution

x2 V

0.603 (26) [2]

0.603

0.311–0.857

Intrinsic hepatic clearance 1-OH-midazolam

x2 CLH,int,M

0.832 (42) [15]

0.709

0.201–1.65

Volume of distribution 1-OH-midazolam

x2 VM

0.887 (48) [8]

1.2

0.442–4.04

Proportional error (midazolam)

0.201 (26) [10]

0.192

0.134–0.264

Additional error (midazolam)

0.0001 FIX

0.0001

–

Proportional error (1-OH-midazolam)

0.164 (91) [33]

0.155

0.000b20.242

Additional error (1-OH-midazolam)

0.0001 FIX

0.0001

–

1-OH-midazolam

Interindividual variability (x2)
0.551–1.16

Residual variability (r2)

CI, confidence interval; PK, pharmacokinetic; RSE, relative standard error.
a
Bootstrap results based on stratified bootstrap sampling for patients receiving an intravenous, an oral, or twice a dose administration. The median and 90%
confidence interval are calculated based on 37.8% successful runs and runs with estimates near a boundary.
b
The 5% percentile reached the lower boundary of 0.2 mL/h and 0.1*1024, for CLG,int and the proportional error for 1-OH-midazolam, respectively. Interindividual and residual variability values are shown as variance estimates.

small overprediction for the low concentrations of midazolam.
In addition, the prediction of the data was unbiased, as
shown in the normalized prediction distribution error analysis
(Supplementary Figure S2), with slightly overpredicted variability in the metabolite concentrations.
Intrinsic hepatic clearance was much higher and also more
variable than the intrinsic gut wall clearance (Figure 2a).
Figures 2 and 3 show the estimated and derived model
parameters related to the intestinal and hepatic metabolism
in preterm neonates vs. bodyweight. The median total
plasma clearance by the liver was 0.181 L/h (range 0.03–
0.79 L/h; Figure 2b). As both the intrinsic gut wall and
hepatic clearance were found to be very low (Figure 2a), the
extraction ratios were very low for both organs, with a median
of 0.04 in the gut wall (range 0.026–0.046) and a similar
median of 0.04 (range 0.01–0.31) in the liver (Figure 2c).
Based on the extraction ratio in the gut wall and liver, the

fraction escaping gut wall metabolism (Fg) and the fraction
escaping hepatic metabolism (Fh) can be calculated and the
median values are both 0.96. Figure 3 also shows the total
bioavailability for all preterm neonates in our study, as calculated based on the fraction absorbed (Fa), Fg, and Fh according to Eq. 5. A very low first-pass metabolism was observed
with 92% of midazolam entering the systemic circulation in a
typical preterm neonate of 1.1 kg, but the overall range of
percentage entering systemic circulation varies largely
between 67% and 95%. Model-based simulations of plasma
concentration-profiles show limited differences in median
plasma concentrations of midazolam after oral and intravenous administration due to the high bioavailability of 92%
(Figure 4a), whereas the concentrations of 1-OH-midazolam
after oral administration are higher for the first 4 hours postdose compared to the 30-minute infusion, due to presystemic
metabolism (Figure 4b).

Figure 2 Intrinsic clearance (a), total plasma clearance (Eq. 8) (b) and extraction ratio (c) are plotted vs. body weight, in which values
are given for the gut wall (䊏) and the liver (䊊).
www.psp-journal.com
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DISCUSSION

Figure 3 Bioavailability in the gut (Fg) and liver (Fh), and total
bioavailability (Ftotal) in preterm neonates.

A sensitivity analysis showed that blood concentration predictions would change <1% for both peak and trough concentrations in case the values for tissue volumes and tissue
blood flows were altered with 6 50%. In addition, no significant change in parameter estimates was found when the
parameters were re-estimated based on the same changes
in tissue volumes, nor did different ka values impact estimated and derived clearance and bioavailability parameters.
However, an increase of 50% in intestinal and hepatic blood
flow resulted in an increase of 20–30% and 50% in the estimated intrinsic intestinal or hepatic clearance, respectively,
and vice versa without profound changes in extraction ratio
and bioavailability. Changes in intestinal length (which contributes to the flow term in the gut wall (Qgut), that accounts
for the permeability through the enterocyte (CLperm) and the
villous blood flow (Qvi)) did not result in different blood concentrations (change <1%), although the re-estimated intrinsic clearance in the gut wall changed 118 or 232% for an
increase or decrease in intestinal length, respectively. The
change in fraction unbound in blood for either midazolam or
1-OH-midazolam was inversely correlated with the same
fractional change in estimated hepatic intrinsic clearance.

Using a physiological population PK model in which both
physiological information and midazolam and metabolite concentrations after oral and intravenous administration were
used, we were able to distinguish between intestinal and
hepatic intrinsic clearance of midazolam in preterm neonates. The PK data used to estimate the CYP3A-mediated
midazolam clearance came from a unique dataset with a
crossover design in which preterm neonates received both
an oral and an intravenous dose, allowing to study both the
first-pass and systemic metabolism. Our physiological population PK modeling approach, which has already been
applied in healthy adults,22 was also able to describe the
absorption and disposition of midazolam in preterm neonates. The results show that the CYP3A-mediated intrinsic
gut clearance is much lower than the intrinsic hepatic clearance (Table 2, Figure 2a), whereas in healthy adult volunteers this difference is reported to be smaller (ratio of 340
in preterm neonates vs. 60 in adults).22 Although this indicates a difference in maturation of CYP3A activity in the gut
wall and the liver in preterm neonates, both the intestinal
and hepatic extraction ratio of midazolam in preterm neonates were very low (median of 0.04 each). This results in a
very small first-pass effect leading to a high total bioavailability of 92.1% (Figure 3) and almost identical concentrationtime profiles after intravenous and oral administration (Figure 4a) for the CYP3A-substrate midazolam in preterm neonates. For the metabolite, however, an increased plasma
concentration can be observed in the first 4 hours after oral
administration due to the presystemic formation of the
metabolite in both the gut wall and liver (Figure 4b). In
adults, much higher median extraction ratios of 0.59 and
0.34 have been reported for the gut wall and the liver,
respectively,22 resulting in a lower total bioavailability of
around 30% in adults.
The intrinsic gut wall clearance values we obtained in
preterm neonates were found to be lower than the values
reported in adults. Additionally, in preterm neonates, the
intrinsic gut wall clearance was much lower than the intrinsic hepatic clearance, and this difference was much larger
in preterm neonates than in adults.22 This could be due to

Figure 4 Model-based simulations of midazolam (a) and 1-OH-midazolam (b) pharmacokinetic profiles following a 0.1 mg/kg dose via
an 30-minute infusion (gray lines) or orally (black lines). The solid lines represent the median plasma concentrations and the dashed
lines show the minimal and maximal achieved concentrations of midazolam in the studied population.
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the immaturity of enterocytic CYP3A enzyme activity in this
population.36,37 The activity in the gut wall has been
reported to be lower with decreasing age,37 but also conflicting activity values have been reported.36 Besides the
activity, the abundance of the CYP3A enzyme, reflected by
a smaller number of milligrams of microsomal protein per
gram of intestine,37 as well as the smaller intestinal surface
area led to a lower total intestinal CYP3A activity in preterm
neonates compared with adults. The smaller surface area
was calculated in our study based on intestinal length (70–
157 cm for infants with a postconceptional age of 24–40
weeks without gastrointestinal malformations undergoing
laparotomy,27 which is in agreement with other literature38,39 and on the mean intestinal radius of 1 cm.26 A
sensitivity analysis showed that with a decreased intestinal
length, both the flow term that accounts for villous blood
flow and permeability (Qgut) and the gut wall clearance
(CLG,int) decreased, resulting in the same reported extraction ratio of 0.04. Furthermore, preterm infants have an
underdeveloped intestinal barrier,15 and neonates with a
gestational age <34 weeks have a higher intestinal permeability,16 which could be due to differences in the intracellular structures that regulate the intestinal permeability.40 In
our model, the permeability factor CLperm25 accounts for
the intestinal surface area and the permeability of the intestinal barrier in preterm neonates. Food in the gastrointestinal tract may alter the gastrointestinal physiology, including
the motility patterns, intestinal transit time, and the local
blood flow,41 but was not accounted for in our model
because the exact times of parenteral and enteral feeding
were not recorded during the study.
The intrinsic hepatic clearance obtained in our study in
preterm neonates was very low compared with reported
values in healthy adults (6.7 L/h and 1,620 L/h in preterm
neonates and adults, respectively).22 The neonatal liver is
relatively immature shortly after birth, and its functional
capacity in bile synthesis, detoxification, and metabolism
increases during the early postnatal period.42 Fetal and
neonatal livers have different bile acid synthetic pathways
than adult livers, and the bile acid pool is reduced,42 limiting
the probability of biliary excretion and enterohepatic recirculation of drugs in preterm neonates. The maturation of liver
function is not a linear process, as the drug metabolizing
enzyme expression changes nonlinearly during development.3 In the fetal liver, 30–60% of adult values in cytochrome P450 content is found and the total hepatic CYP
content increases after birth.43 Of these CYP enzymes, the
CYP3A family is the most abundant.8,13,44 The CYP3A isoforms show a different ontogeny profile, with CYP3A4 activity
increasing in preterm neonates with increasing age, CYP3A5
activity seems to be stable from neonatal life to adulthood,
whereas simultaneously CYP3A7 activity declines in neonates.44 Within the group of preterm neonates included in
this study,19,20 we could not identify a trend in hepatic intrinsic clearance with gestational age or postnatal age, which
can be explained by the small age range of the studied population. Due to the lower intrinsic hepatic clearance, the
hepatic extraction ratio is very low in preterm neonates compared with adults, resulting in a much higher hepatic bioavailability than expected based on adult values. This has been

previously reported by Salem et al.45 who found that the
hepatic extraction ratio of midazolam increased with age.
They found that the ontogeny of hepatic enzyme abundance
and to a lesser extent the smaller number of microsomal protein per gram of liver contributed to the observed differences
between preterm neonates and adults.45 Based on the
hepatic intrinsic clearance, the hepatic blood flow, the fraction unbound in blood, and the blood:plasma ratio, the total
plasma clearance can be calculated (Eq. 8). The plasma
clearance ranged from 0.03 to 0.79 L/h with a median value
of 0.181 L/h (Figure 2b). This is in agreement with other
reported values of 3.9 mL/min (0.23 L/h) for preterm neonates with a mean gestational age of 32.1 6 2.8 weeks12
and higher than the reported values of 0.783 mL/min
(0.05 L/h) and 0.104 L/h in very premature neonates with a
mean gestational age of 27 (24–31) and 27.9 (25–30)
weeks, respectively.46,47
The RSE percentage for the estimated intrinsic gut wall
clearance value and high range of the 90% bootstrap confidence interval of this parameter together with a high number of unsuccessful runs in the bootstrap and a high
condition number suggest overparameterization of the
model. In a population modeling approach, this could warrant a re-evaluation of the structural model, however, our
structural model and a subset of parameter values are
based on physiological knowledge and physiologically
based pharmacokinetic principles, and only the values of
the remaining subset of parameters were estimated from
concentration-time data using population modeling principles. The high RSE% and 90% bootstrap confidence interval can, therefore, be interpreted to mean that the data do
not support a very precise estimate of intrinsic gut wall
clearance.
For the structural model a few assumptions were
included, which were evaluated in a sensitivity analysis.
Plasma albumin concentrations were calculated based on a
reported age-based formula by Johnson et al.5 in term neonates, assuming the preterm neonates to have the same
concentrations as a 1-day-old term neonate. In addition,
only plasma albumin concentrations were taken into
account. Free fatty acid (FFA) concentrations are known to
reduce protein binding of diazepam in neonates,48 and
could result in a higher fraction unbound in blood for midazolam as well, but this was not taken into account, nor
were other factors that could impact protein binding of midazolam. Our findings about the low gut wall and hepatic
extraction leading to a small first-pass effect and high bioavailability in preterm neonates are, however, not influenced
by these assumptions. Even though the fraction unbound
and the intrinsic hepatic clearances are related, a different
fraction unbound would increase the intrinsic clearance proportionally, yielding no net changes in extraction ratio or
bioavailability. Furthermore, tissue volumes and organ blood
flows are not directly measurable in preterm neonates.
Therefore, allometric scaling was applied to scale the organ
blood flows from data in term neonates7 to preterm neonates. The sensitivity analysis showed that changes in
assumed organ blood flow are correlated with the estimated
organ clearances: with an increased intestinal blood flow,
the intrinsic intestinal clearance was estimated higher and
www.psp-journal.com
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the assumptions of the hepatic blood flow were found to
correlate with the estimated intrinsic hepatic clearance.
However, in this study, also the extraction ratios and bioavailability derived from the estimated parameter values
remained unaffected by changes in organ blood flows and
would, therefore, not have an impact on our finding that the
first-pass midazolam in preterm neonates is much smaller
than in adults.
To conclude, the developed physiological population PK
model was able to distinguish between CYP3A-mediated
intestinal and hepatic metabolism of midazolam in preterm
neonates. Intrinsic clearance in the gut wall was much
lower than in the liver, but the median intestinal and hepatic
bioavailability were both very high. This indicates a very low
first-pass effect by intestinal and hepatic CYP3A-mediated
metabolism in preterm neonates compared with adults. Furthermore, the variability in bioavailability was very high, indicating that oral dosing may yield large differences in drug
exposure within this population. Overall, the PK of midazolam and its primary metabolite 1-OH-midazolam were welldescribed by the model, and this physiological model may,
therefore, be used to predict the first-pass effect and systemic metabolism of midazolam and other orally administered CYP3A substrates in preterm neonates based on the
physiological and drug properties.
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